Ladies and gentlemen, thank you for standing by, and welcome to Dassault Systèmes 2021 Q4 and full year ending presentation. At this time, all participants are in listen-only mode. After the speaker presentation, there will be a question- and- answer session. To ask a question, you will need to press star and one on your telephone keypad. I would now like to hand the conference over to the speaker today, François-José Bordonado. Please go ahead, sir.
Thank you, Roberto. Good morning, everyone. This is François-José Bordonado speaking, Dassault Systèmes Investor Relations. From the company, we have Bernard Charlès, our Vice Chairman and Chief Executive Officer, Pascal Daloz, Chief Operating Officer, and Rouven Bergmann, Chief Financial Officer. I would like to welcome you to Dassault Systèmes fourth quarter and full year 2021 webcast presentation. At the end of the presentation, we'll take questions from participants. Later today, we will also hold a conference call. Dassault Systèmes results are prepared in accordance with IFRS. Most of the financial figures in this conference call are presented on a non-IFRS basis, with revenue growth rate in constant currency unless otherwise noted. For an understanding of the differences between the IFRS and non-IFRS, please see the reconciliation tables included in our press release appendix.
Some of the comments we'll make during today's presentation will contain forward-looking statements, which could differ materially from actual results. Please refer to our risk factors in our 2020 document and 2021 half year annual report. I will now hand over to Bernard Charlès.
Thank you, François. Good morning or good afternoon to everyone. It's always a special moment to be reporting to you the full year and also providing guidance for the subsequent year, 2022. It's even more important moment for Dassault Systèmes with the expansion and the strengthening of the executive team, and I will cover that. But let's start on the 2021 highlights. We are very pleased with the achievement of 2021. The revenue was up 11% as you have seen it. Operating margin is significantly up also at 34.3% and resulting in an EPS up 26% with a great dynamic, a strong dynamic for 3DEXPERIENCE, the platform plus 15%. Also the cloud dynamic, we are pleased with it, up 23%.
All the elements put together, I think, establish a strong base for sustainable growth. I think it has to be put in perspective of what happened in 2019, 2020, 2021, and also perspective about our plan for 2024. We will cover those topics. We are walking the talk, I think. If you look at what we said and what's happening, I believe that the positioning of the company that we formulated almost 10 years ago to say the economy is going toward an experience economy. The value is in the usage and the experience more than the product itself. I think it's substantiated almost in every sector we serve today, and there are so many examples that we see, and I will illustrate a few of them.
The second topic that you have seen is the creating a new reach by looking at the economy from the manufacturing sector, everything which is produced, the life science diversification, and also the infrastructure. Finally, the intrinsic evolution of each of those sectors at the center of which is the challenge of making the economy more sustainable. I think we are connecting those dots at Dassault Systèmes with the virtual twin experience and the capacity to systematically use virtual twins to imagine, create, produce on life cycle things. I would like to insist on that point because we are indeed creating virtual worlds which are not fake. It's the reality or the to-be reality. We see it everywhere in mobility, in space, aerospace, new equipment, industrial equipment, autonomous system, in the way we build and construct things.
Indeed, virtual world extend and improve the real world for us. It's far beyond a metaverse. It's the improvement of the real world, and this is where we have a unique positioning. We are building experiences that we deliver to clients in three of those sectors of the economy. We are building experiences to design an airplane, produce an airplane, life cycle an airplane, for precision medicine, for construction methods to have a more sustainable world in cities. All this is centered on the human side as an actor, as a citizen, an actor or worker, as a citizen, as a passion, precision medicine. This is what is represented in the way we are approaching those industries.
Clearly, today, I must say that we are becoming the de facto industry standard in many of those industry segments that, you know we are positioned, but we are also expanding the reach of what we do from engineering, manufacturing to really sustainability on supply chain. We represent it with this famous infinity loop, which is how do you create value? How do you produce this value? How you create experience, and you deliver experiences to to clients, citizens? In some way, our clients are driving us to expand our platform on software usage to reach their own consumers. That's why the virtual twin experience is really a significant differentiation to understand and build the what, to define how you make it.
Virtual twin experience of a bioreactor is an important differentiator for companies as it is for manufacturing companies, or virtual twin experience for health practices is also a significant differentiation. There is no need for us to use metaverse. We use virtual twin experience because it says what it does. Here is a video that illustrates in the life science sector that idea.
This is a clinical research site. This is also a clinical research site. This is clinical data. This is also clinical data. This is a person participating in clinical research. This is also a person participating in clinical research. Clinical trials don't look the same today as they did yesterday, and they won't look the same tomorrow. As more and more technology is used to decentralize trials, the entire clinical trial experience is transformed for everyone involved. Decentralized trials provide greater access to research, which drives higher and more diverse recruitment rates, enhances the patient experience, and ultimately enables faster trial timelines. This new reality has also raised new questions. Patients can now participate in a trial from anywhere, but can they maintain the human connection to their study teams?
Doctors and researchers can now collect more data in different ways, but do they have the tools to do so efficiently? Will they be able to quickly derive meaning from those data? Medidata has been preparing for these challenges for the last 20 years. Now, with the launch of our newest solutions to enable decentralized clinical trials, we're ready to continue leading for the next 20 years. Because a suite of tools perfected for the last mile of connected patient research has inspired a much greater journey. We are imagining and paving the way for a revolution in connected healthcare for patients, better experiences in everyday health, better outcomes measurement, and better disease prevention, new ways of collecting and utilizing data that will ultimately make us the leader in a world of validated biomarkers, synthetic control arms, and digital twins.
Digital reflections of health and disease, paving a pathway for truly personalized and predictive healthcare worldwide. From right here, we stand on decades of success in human research to shape the future of human health.
continue to focus on being game changers in every sector we serve. When we are game changers, I think you create long-term sustainable growth, but you also are constrained with the speed at which each market transforms itself. This balance between the speed of market transformation and the game-changing aspect of what we bring is really becoming visible in manufacturing industries, life sciences and healthcare, and infrastructure. We believe that this is exactly why Dassault Systèmes is using science and technology to really serve a more sustainable world. I would like to take a few examples which are quite interesting because they illustrate well connecting the dots. We are deploying the 3DEXPERIENCE platform, what we call 3DEXPERIENCE HomeByMe, on the cloud at IKEA.
At IKEA, the most important thing is to be inclusive to their consumers when they want to buy, for example, a kitchen. Clearly what we have noticed is the incredible fast adoption of basically a virtual twin experience in an omnichannel 3D-based approach to connect the coworkers of IKEA, about 10,000 of them in many countries, in 53 countries, 83 languages, and connecting them with consumers. I think people never thought Dassault Systèmes could reach consumers that way. We are taking it very seriously as we are for precision medicine or as we are for the way we are going to help build new cities. In a few months only, we reach more than 1 million users. I think it will be multiple millions of users who are connected with the coworkers to get what they need.
This is a good illustration about how powerful the virtual twin experience can help change the relationship between the consumer and the provider of the product and services associated with it. More to be seen in this area, because as you will see later on, the dynamic with Centric PLM serving consumer companies basically is also extremely strong and was still are. I think, Pascal and Rouven, if I remember well, about 80% growth last year, so we see vibrant dynamic in this area. Another example is, of course, in the production environment. The virtual twin used for design, production, and optimization on supply chain is also game changer. It goes far beyond 3D adoption. It's really the systematic approach to a virtual world to improve what actually happened in the real one.
Pirelli is an excellent example of that, and we deliver not the toolkit. We deliver experience ready-to-use to do the job they have to do. We call them industry solutions on industry processes. Another example is the adoption of the 3DEXPERIENCE platform by Perrigo, 130 years as the company providing products for consumers in very differentiating. Then they are using the platform to do the experience that we call License to Cure, perfect formulation, perfect package. We all know that this sector is going through a massive transformation to justify that they are becoming sustainable in terms of the products they use and how they are recycled. That's a concrete illustration of the platform phenomenon.
I just use those because some others are coming. Of course, you may notice that we are strengthening beautifully. I'm so proud about that, the executive team of Dassault Systèmes. Pascal has been doing an amazing job as both CFO at first. I wanna remind everyone that before he was leading all the brands of Dassault Systèmes, did the strategy before. 20 years of experience, understand well the company and expanding his role to really connect the dots of everything we do with a new generation of executives around him. They are in place. They are very talented. Welcome to Rouven.
I'm so pleased that you are here, Rouven, with us around the table, which shows that we can have significant acquisition and promote great talents to be driving the future of Dassault Systèmes, which will give an incredible possibility for Pascal Daloz to continue to develop as Chief Operating Officer the performance of the company on developing this new reach that we need to have because the potential that we have built with our new ambition is very high. In conclusion, from my part, what I would like to say is that, you know, the talented people are joining us because they love our purpose, harmonizing product digital life. Customers are taking us seriously on sustainability because they know we can help them build the next generation portfolio.
This is what they are doing now for the next five or 10 years across all sectors of the industry. I think that the human dimension, the social dimension of what Dassault Systèmes is doing, is a serious value and needs to be taken into account because I believe this is where virtual twin experience can make the difference. With that, I give the floor to Pascal.
Thank you, Bernard. Hello, everyone. I hope you are doing well, and thank you for joining us today. Speaking about the performance, Bernard, let's turn to our financial results. I think the strong business momentum we experienced through the year continue in the fourth quarter, resulting in performance well aligned with our guidance. Starting with fourth quarter top line, year-over-year comparisons, what could we say? First one, total revenue grew 10% to EUR 1,370 million, above our 7%-9% range. The software revenue also grew 10% and all organically. That's very important to remind. Licenses and other revenue rose 15% to EUR 348 million, well above the guidance and back to 2019's level, which is also a very important point to notice.
Subscription and support revenue increased 8%, driven by high double-digit subscription growth, reflecting strong Medidata, obviously, contributions, but also the 3DEXPERIENCE performance and also more and more, you know, product line like ENOVIA, which is more and more used and consumed through a subscription model. Recurrent revenue represent today 72% of the total software revenue. Zooming on the services revenue was up 10%, and I think we achieved services growth margin of an amazing 27.1%, substantially better than compared to last year. I think it's the result of all the effort we made to improve the efficiency during the pandemic periods.
We are at a point where by now, you know, to fulfill all the new project we signed this year, we probably need to increase significantly the capacity and continue to develop the ecosystem to make it happen. From a profitability standpoint, the fourth quarter, we deliver a strong operating margin, 36.8%, well aligned with our guidance of 36.4, when you take into account the currency effects impact. The EPS grew 17% to EUR 0.29 compared to our guidance of EUR 0.27-EUR 0.28. Now turning to our software revenue performance by geography. The Americas grew 7% during the fourth quarter, driven by a solid subscription growth. In 2021, the region benefited from a strong performance in high tech, transportation and mobility, life sciences.
You have to remind that now Americas represent 38% of the total software revenue of Dassault Systèmes. Clearly between the geos, we are relatively well balanced, and it was up 13% for the full year. Europe increased 10%, thanks to the strong resiliency through all the regions. In 2021, transportation and mobility, industrial equipment grew double digits also. Now Europe represents almost the same size in America in terms of contribution, so 37% of the total software revenue, up 10% for the full year. Asia, finally rose 12%, driven by market expansion. That's to be noticed also, because you remember in Asia, we were really focusing on the core industry, and more and more we expand outside of the boundary of the auto and aerospace sectors. It's particularly true in Japan, India and Southeast Asia.
During the fourth quarter, China grew 10% on the back of a strong base comparisons compared to last year, remember, and 19% over the full year, which is an amazing performance. In 2021, Asia represent 25% of the software revenue, up 12%. Now let's zoom on the product line performance. We're gonna start with industrial innovation software first. The revenue rose 8% to EUR 682.3 million, driven specifically by SIMULIA and DELMIA, which are the double digit growth, thanks in part to large clients and customer wins. As I was saying, ENOVIA showed a strong subscription growth and CATIA reach back the 19th levels, which is also an important point because we, with CATIA, we are back on our trajectory.
In life sciences, software revenue reached EUR 245.1 million, an increase of 9% for this quarter. Medidata grew 15% on the back against of a strong comparison base. We continue to see a good momentum across Medidata portfolio, so including Medidata Rave, Medidata AI, Medidata Patient Cloud, as well as across end markets, including, you know, obviously the pharmaceutical and the biological companies, but also more and more the research, the contract research organization and the medical devices as well. We also saw a high double-digit growth in attach rate against this quarter, which is extremely important because you remember it was one of the bets at the time of the acquisition of Medidata. From a product lines perspective, the strong Medidata performance was partially offset by a lower than expected BIOVIA revenue.
This was driven by the delay of two large renewal, and we expect to sign both renewal during the first half, so temporary impacts. There was also a strong baseline effect with software revenue up 39% in Q4 last year, if you remember. We are about one year into the life science engagement model. If you remember, a year ago, we decided to gather all the teams together under the leadership of the Medidata management team. Michael Pray, who is leading this, is doing an outstanding job. When you look at, we made significant progress and our deal with the Perrigo deals, Bernard Charlès showed, is a great example because it's not only focusing on the clinical trial per se, but more and more to the rest of the portfolio we are bringing.
We are confident in our strategy to provide life science industry with end-to-end solution that connects, obviously, ideation, development, manufacturing, and commercialization, almost the same way we did in other industries, such as aerospace, decades ago. We believe this is a differentiated capability in the marketplace. Moving now to the mainstream innovation software. Revenue rose 14% to EUR 312.2 million. SOLIDWORKS delivered strong result, with software revenue growth high single digits. We continue to see good adoption of our 3DEXPERIENCE Works family, cloud-based solutions during this period, specifically with most of the new logo we are winning are starting with these, product lines. This is also extremely true in Asia. Centric PLM is performing extremely well with, high double-digit growth revenue.
If we zoom on Centric PLM, I think they are executing extremely well against this quarter, reaching for the full year the milestone of 550 clients, representing more than 4,500 brands. Which is amazing. All with a high level of customer satisfaction. In terms of diversification, you can see we started a few focusing on the fashion brands and to some extent, the outdoors and lifestyles, and more and more we see a good uptake in food and beverage, cosmetics and personal care, and other segments such as also consumer electronics and consumer goods.
Congratulations to Chris Groves and his team.
Yeah. Now, a few words about the growth drivers because delivering numbers is good, but, relying on the growth drivers is even better. Now you can see that for 2021, the 3DEXPERIENCE revenue rose 15% driven by strong subscription growth. It's now representing 30% of the total software revenue, an increase of two points compared to last year. Zooming on the cloud, the cloud revenue increased 23% driven by obviously the continuous trends in life sciences and 3DEXPERIENCE. The cloud now accounts for 20% of the total software revenue, up two points versus last year. All clients, you know, across all sectors are transforming rapidly.
They are turning to Dassault Systèmes, to us, to help them adopt the new models, accelerated innovations, embrace sustainability imperatives, putting consumer patient citizen at the center of the experience. Our strategy is really to enable them this transformation with more and more cloud-native applications or cloud extension to existing on-prem investment when they started a decade ago, you know, to adopt our solutions. That's what the 3DEXPERIENCE platform is allowing us to do. There is not one single path. There are multiple paths for the customers to adopt this kind of solution. Now, a few words on the operating margin. We deliver a strong operating margin of 36.8%.
This was well aligned with our guidance of 36.4%, when taking into account the currency impacts of 40 basis points, and also the 30 basis points coming from higher revenue contributions. Few words on the headcount. I think in terms of headcount, we are well aligned with our objective. We saw strong hiring activity in Q4 and lower attritions. Overall, headcount grew 4% and 6% specifically for research and development. Given our track record of innovation and our missions-driven culture, I think we are confident in our ability to continue to attract and retain top talent over the mid to long-term, and this is one of our priorities for 2022. EPS, the diluted EPS grew 17% to EUR 0.29 and compared to our guidance of EUR 0.27-EUR 0.28, which is EUR 0.01 more, and reaching for the full year EUR 0.95.
This has been driven by the top line performance, but also the strong operating leverage we had this year. This is well reflected into the cash flow and the balance sheets. Turning to the cash flow the fiscal year 2021 cash flow from operations grew 30% year- over- year to reach EUR 1.63 billion, which is converting almost a third of the revenue to operating cash flow. The cash amounts a little bit less than three billion, EUR 2.98 billion. An increase of EUR 831 million versus last year, and an increase of EUR 204 million in 2020, just to have a basis of comparison.
Our net financial debt position on December 31, 2021 decreased by EUR 1,152 million to less than a billion, to EUR 890 million, compared against the EUR 2 billion we had in December last year. This put us a year ahead compared to our initial schedule on our deleveraging objectives. I think this is a outstanding performance and the proof that we can continue to make large deal, large transformations deals without compromising the business model and the ability of the company to continue to invest. Introduction now to Rouven, because I think to discuss the 2022 objective, I'm very pleased to introduce Rouven as our new Chief Financial Officer. As Bernard mentioned, Rouven has played a vital role in integrating Medidata, and it's a real pleasure working together and a successful partnership.
Rouven, you have the floor.
Thank you, Pascal. Before I start walking through the 2022 financial objectives, I want to say that I'm really excited and thrilled to be here today with you in this new role. I've really enjoyed the opportunity to meet with some of you already over the course of the last two years and learn from many colleagues at Dassault Systèmes, in particular you Pascal, since the acquisition of Medidata, which as you know, we've completed about two years ago. A little bit more than two years ago. Now, after the successful integration, I'm really looking forward to getting to know all of you and the broader investment community during this year, and I know we will have lots of opportunities to do so. With that, let me turn to the full year 2022 financial objectives.
We expect the broad-based dynamics we experienced in the fourth quarter and 2022 to continue into 2022. We are focused on driving durable long-term growth. Our growth drivers are well established as highlighted already by Bernard and Pascal. First, we are enhancing our leadership positions across our major brands. Second, we are accelerating the momentum with 3DEXPERIENCE and industry solution experiences, winning new customers and expanding significantly within the installed base. Third, we are focused on delivering new experiences and value with cloud. We will continue the momentum of Medidata and Medidata Patient Cloud, but we will also expand the user base with the 3DEXPERIENCE Works family in the mainstream market. Deliver new value at scale with large enterprise partnerships like what you saw at Renault or Bouygues Construction.
Now, with that in mind, we are targeting for full year 2022, total revenue growth of 9%-10% and software revenue growth in the same range. Now, when thinking about our software revenue growth, please keep in mind that last year we had very strong year of license growth of 23% year-on-year, which brought us back slightly ahead of 2019 levels. Now, for this year, we expect to continue healthy double-digit growth at around 10% up to 12%, which reflects strong demand within our installed base. This trend is more in line with what we saw in Q4 of 2021.
We anticipate recurring software revenue to increase by 9%-9.5%, an acceleration of 100-150 basis points versus last year, driven by continued momentum and subscription growth with cloud and solid improvement also in support revenue, which is also resulting from the very good license growth we experienced throughout 2021. Services revenue is projected to grow between 8%-9%, reflecting the increased activity levels of delivering innovation to our clients across all segments with solid margin performance. From a profitability perspective, this past year, we demonstrated the long-term scalability inherent to our business model. As we said, throughout 2021, we plan to accelerate investments into our business and reengage in activities which were impeded by the pandemic. Accelerating the growth in our workforce, of course, in line with our long-term and midterm plan is our top priority.
As such, we anticipate the non-IFRS operating margin to be in the range of 32.7%-33.1%. Again, this is consistent with our prior communication. Now, let me continue with our proposed objectives for EPS. We expect non-IFRS earnings per share to grow between 3%-6%, reaching EUR 1 at the high end. The EPS guidance assumes a tax rate in line with 2021 levels of about 23.2%. Our financial objectives assume euro to U.S. dollar conversion of about 1.17. I will provide now some additional color on what to expect for Q1. As you are aware, our business has some level of seasonality, and we expect to see growth rates progressing throughout the year.
We expect Q1 total revenue growth of 7%-9%, with software revenue increasing in the same range and services revenue up 5%-7%, driven by continued product-based momentum across our geos. We expect the operating margin at a range of 32.3%-33%, with an EPS growth of 3%-7% versus last year. Now, as you heard from all of us during this call, we're confident in the long-term opportunity ahead and look forward to keeping you appraised as we progress throughout the year. With this, I'd like to hand the call back to Pascal.
Just few words to conclude. I think, Bernard said, but the stage is set for the future growth. When you think about it, our long-term strategic vision has been validated, and it's paying off now. The investment we made 10 years ago, you know, to develop the experience economy, whatever we are talking about, the platform, the virtual twin experiences, our industry solution and the cloud are a durable competitive advantage. In parallel, I think we are also helping our clients to transform to a sustainable economy, and it's becoming a real opportunity to deepen and expand our partnership with many of our customers. If you combine the two, I think we have a strong secular driver underpinning the growth across almost the three major sectors of the economy we want to serve.
In addition, we are convinced we have the right leadership team in place to execute against the tremendous opportunity before us. Last but not least, our commitments to clients, you know, drive our strategy, and thanks to them, for their continued trust, is making also a difference. Finally, I think Rouven and I are, I would say, impatient to be back on the road and to see you face-to-face hopefully, obviously in the next coming weeks, if not months. I think it's time for the Q&A. Bernard, Rouven, and I will now be happy to take your questions. Thank you.
Roberto, let's start questions.
Thank you so much. As a reminder, if you wish to ask a question, please press star one on your telephone keypad. We have the first question from the line of Stacy Pollard from JP Morgan. Please go ahead. Your line is open.
Oh, thank you very much. Two questions from me. First of all, maybe Pascal and Rouven, what are the factors influencing margins, whether you hit the top end or the bottom end of that range? For example, how has your hiring been? I know your headcount was up 4%. It seems like you might need to do more there. To what degree is wage inflation sort of a factor? That's question one. The second one, a bit more strategic.
Bernard, you already discussed in your opening remarks, but how do you think about the opportunity in the metaverse? And is the consumer space something you could target directly? Like, is there an opportunity there, or is it mainly that you'll sort of interact at the consumer level via the corporate customer?
Thank you, Stacy. Pascal? Or maybe Rouven should answer that. Rouven, yeah, go.
Thank you, Stacy, for the question. Yeah, for 2022, of course, we are back on track as it relates to the ability to hire and grow. Q4, we already were able to prove that. The attrition is starting to come down. In Q4, the hiring level was very healthy. I think if you look now into 2022, we are expecting to grow quarter-over-quarter between 300 and 400 net per quarter. That means we are probably going to hire about 1,000 to 1,200-1,300 people per quarter. That is factored into our guidance and financial objectives.
You know, because we started to see that traction in the second half of the year, we carry over this effect into 2022. We factor this in that as well. From an inflation standpoint, yes, we've adjusted our compensation on average around 5%. I think this is the industry norm right now, and it's the right thing to do for our employees. If you put this all together, of course, when we talk about margin, we also have to talk about the top line. We are confident in the 9%-10%. We see the acceleration in subscription at very healthy margin levels.
I think we are well-positioned with regards to the margin, which, by the way, when you look at it at 33%, that's back at the level of where we were 2019. I think that's the level where we believe it's a very healthy margin level that gives us the flexibility to do the right level of investment to take advantage of the secular growth drivers that, you know, Bernard and Pascal talked about. I think that's our job to ensure that we find the right balance. I think in 2022 objectives, that's what we've reflected.
Regarding the second question, Stacy, about the topic of metaverse. We think that, like, by the way, what Tim Cook has been saying at Apple, on that same question, it's about virtual reality.
It's about, for us, about virtual twin experience. This is what we've been doing for 40 years, creating the first digital 3D airplane, cars, now almost everything. I believe that the great trend to have new devices, what I call 3D mobile devices, to make 3D pervasive across the society is happening and accelerating. The part we will play in terms of opportunities for growth is to help our clients reach their own consumers. This is why this morning I used the incredible showcase of IKEA. It's one example. But in our daily life, we see how many things we want to buy or we desire to have in our homes, in our life. It's very difficult sometimes if you don't see the real thing to understand, will it fit under the window?
Will it fit in your house? Whatever. It's the case very often. It's a question of relationship between you and your life and the things you see on the screen in a virtual world. This alignment is coming fast. We are proving it with IKEA in many other situations. I call this the 3D omnichannel approach to really connect with humans. Same is happening in the medical sector. If you do a surgery on a virtual heart experience, scale and reality is important if you want to prepare first to educate the patient to know what the physicians are going to do. It's a huge set of opportunities for us, Stacy, and we are playing it, and we call it virtual twin experience of the to-be or of the as is.
I think people understands it very well, and our customers loves it.
Great. Thank you.
Next question, please.
Thank you for your question. We have the next question from Michael Briest from UBS. Please go ahead. Your line is open.
Yes, a couple from me. Thank you. Just in terms of Medidata, I mean, tough comps in Q4, so I appreciate the slowdown, but could you talk about the expected growth you see this year for Medidata? And then on the cloud, I think Pascal, a year ago, you said it was 17% of 2020 revenues and it's 18% today. Not massive, but if it's 17%, it means all of the recurring revenue growth was coming from cloud. So can you talk a little bit about the dynamics of the sort of shift from support into cloud? How much of that's occurring?
I guess in order to get to 33% of revenues in four years' time, if it grew two points rather than three points last year, you have to accelerate. What sort of trajectory, maybe Rouven, this is for you, would you expect cloud to be this year in terms of proportion of sales and is it quite a linear progression or will it accelerate in the out years? Thank you.
Okay. Rouven, maybe you can take the first one on Medidata.
Happy to.
Without the gallery on.
No, thank you, Michael, for the question. It's a good opportunity to highlight the performance of Medidata. In fact, we see, you know, the sector, the life sciences sector operating at a very high level. We saw the activity and investment level from a macro perspective, of course, very favorable. The pandemic has really changed the status quo of this industry because I think I wanted to point back to what Bernard said before, where it's really hard to find the right timing in terms of that when the right time is when the industry transform, you have to be ready to take advantage of that. I think Medidata is a fantastic example where we were investing really ahead of time for many years.
With the change of the pandemic to the landscape in terms of decentralizing clinical trials, in terms of the importance of AI and data analytics to simulate an advanced evidence generation, Medidata was really ready to take advantage of this opportunity. I'm saying this, Michael, because those trends are here to stay, right? They are not temporary because we were just elevated by a pandemic. Those trends are here to stay. In 2021, the growth was of course elevated because when you compare it to 2020, we had some softness in the first half of the year of 2020. We saw that clearly reflected in this very strong growth in the first two to three quarters of 2021.
In the fourth quarter, Medidata grew 15+% , so it was more than 15%. I think very strong, because on a comparability of a very strong Q4 of 2021 as well. Why am I saying this? Bookings levels were almost at record level. Our backlog continues to grow at very healthy double-digit growth to support the 13%-15% growth range that we have set as our target. I think Q4 is a good representation of what to expect in 2022 in terms of Medidata's growth. The 13%-15% growth range is that what we are targeting.
Of course, now at a business that's almost $1 billion in revenue, where you have a certain baseline effect as well. You really have to factor that into the growth calculation. From a growth driver standpoint, Medidata continues to grow through the expansion into Patient Cloud and data analytics and AI, which continues to drive a broad-based portfolio supporting the growth objective. With that-
The second question you asked Michael was related to the cloud. As I was telling you, it's 200 basis points more in the mix of the total software revenue this year, so 20% compared to 18% last year. If you look at the different contributors, right now, Medidata is by far the largest contributor to the cloud dynamic, around 80%. 20% is coming from the rest. The rest being specifically ENOVIA, CATIA, and to a certain extent, SIMULIA as well. Where we see the mix in terms of the different contributors going for the next few years, it will be much more balanced.
I do expect Medidata's in the objective I gave to be a third of the revenue in 2025 to be around EUR 60-EUR 65. Which basically means the rest will grow faster, and the rest will be specifically ENOVIA, where we see more and more the customer adopted the subscriptions and the cloud model for them because it's very suitable for the collaborative environment, and it's giving the flexibility with the named-user approach we have generalized. SIMULIA, because the computing power is also something giving the ability to have those kind of solution being affordable for also the mainstream and the midsize market. We see traction along this way, and the Works family is also benefiting of this.
Last but not least, the new generation of SOLIDWORKS, is definitively, I mean, very suitable for the cloud approach because it's a way obviously to get access to the feature and the functionality, but it's a way to connect easily with the rest of the portfolio we have. That's the most important right now. The second thing is the 3DEXPERIENCE platform is becoming the cornerstone also for the mainstream market, and the only way to make it affordable is also through the cloud. If you combine all those elements, you will land with a mix, which is the one I just described. From 80% Medidata contributions to 60%-65%, the rest will be all the product line I just described.
Pascal, would you expect to add about 300 basis points a year, or will it be more back-end loaded than that?
No, I mean, Bernard say, in an elegant way, he say, "You could have the solution. There is one thing you are not mastering, is the market adoption." The mainstream is probably something we could control because it's much more a push than a pull. When you are talking about large customers, take the example of Renault. I mean, you need a lot of,
Point to be connected and aligned before to have a large company like Renault to take the decision to move 100% to the cloud. All the large customers we have have a 10-year roadmap, all of them. The problem is not anymore the roadmap. None of them will shift overnight. That's the reason why you could accept that from one year to another one, you could have some volatility, I would say, in terms of the contributions. Because otherwise, I mean, if we would have been able to give you with precise numbers when the customer will migrate, means we are in full control of their decision process, which is not fully the case. Okay?
Thank you.
Next question, please. That's Mo.
Thank you for your question. We have the next question from Mohammed Moawalla from Goldman Sachs. Please go ahead. Your line is open.
Thank you. Morning, Bernard, Pascal, and Rouven. I had a couple from my end as well. Firstly, Bernard, you know, obviously we're hearing, IT spending and the broader environment is very robust. We're also seeing kind of larger, more kinda strategic engagements happening across the different sort of segments within software. I'm just curious from your vantage point and as we're kind of now coming out of the pandemic, we saw the Renault deal, but how do you see sort of some of these bigger strategic engagement discussions developing?
How should we see that sort of coming through in terms of your business, and not just on the kind of core automotive or transportation, mobility and side, but also in life sciences? If you could comment on that and how you expect those sort of sales cycles to develop. Second question, obviously, I think you alluded to this, Pascal, that the balance sheet is kind of delevered ahead of kinda your expectations. You're looking to continue to diversify. Can you remind us again in terms of kind of your approach on M&A, what are the kind of particular verticals that are perhaps a priority today, in making those strategic moves on, given you know where different industries are digitizing?
Is your thinking there kinda changed to accelerate the process? Thank you very much.
Mo, on the first item, which is clearly for our existing base, the migration toward going through the experiences, as Pascal just said, it's very clear in their customer roadmap. It's not anymore a question of should we do it. It's about how do we stage it. It's very clear on. I think it's creating a strong visibility for us. The second thing that it does as an effect related to your question is it's creating a new reach. For example, at Renault, but I could also mention other clients like Airbus or even Boeing now with their massive transformation going on. The platform is becoming a platform used for costing, supply, so not only engineering, but manufacturing engineering, optimization of the plant, evaluation of the product in operation.
We mentioned Schindler a few months ago, where we really are evaluating the introduction of the platform to support the world installed base of elevators and escalators. That's a world of reach that was not possible without the platform are now becoming available. We are very cautious to put the pilots for growth. Dassault Systèmes is Dassault Systèmes. We put the pilots for growth first, and then we build on them. That's what is happening. We are very confident. I have to tell you, the mood with the customers to really embrace the platform phenomenon is very strong. I remind that we mentioned Toyota in the past. We mentioned Renault now. We mentioned Boeing at some point in time. We mentioned Airbus. I mentioned Schindler.
I could take a lot longer list of those clients and say this move is on and will not stop.
Regarding the the balance sheet situations, you're right, Mo, we will be fully deleveraged somewhere H1 this year, 2022, which give us, you know, room to maneuver. The M&A policy has always been the same. We have the bolt-on, so it's an ongoing flow of acquisition we do for, you know, between almost 100 and 300 million per year. You have, because I think this is your question, the big move we can do. We have big move we could consider in all the three sectors of the economy, at parity, I mean, in terms of where do we want to focus. If you continue to put pressure on the tech sectors, maybe some of them will become affordable for us.
That's probably the only good news of the situation right now. Do not expect that I will disclose our thinking process during this call. You have to wait a little bit.
On the dynamics. If Mo, I forgot to answer the question on, you specifically said also on life science connecting the dots. Let me be clear on that. We use Perrigo on purpose. And we have many other customers where they were Medidata only, and now they are seeing the value of bioreactors. Virtual twin for bioreactors. They are seeing the value on the front end in research with BIOVIA on what we call OneLab, which is an excellent showcase about how we connect research lab, clinical trial and bioreactor. The showcases are there. In fact, it's a discovery for this industry, as Rouven said.
That sector was more document-based than fully virtualization-based and is discovering the virtualization as opposed to just digitizing basic documents. We need to calibrate how fast we go because we want to make them successful.
That's great. If I could slip for
Please go on.
Rouven. Thank you. Rouven, just as we think about sort of the Q1 guidance,
Yes.
Simply from the kind of tough comparisons, or is it? 'Cause I think on the recurring side, the comp is not as tough. Just can you help us kind of understand the thinking around the kind of recurring guidance you've given at least the bottom half?
Yes.
What kind of portion is that?
I think, Mo, the simple answer is we, you know, we are growing progressively throughout the year. We are forecasting 100-150 basis points improvement in recurring revenue. Certainly driven by accelerated growth in the subscription line, but also in recovery of support because as a result of the really very strong performance in licenses in 2021. We just want to gradually progress into the year. I think it's a good and prudent way to structure the full year outlook. That's the summary. There's no systematic headwind for Q1.
It's simply, you know, we are progressing from a very solid Q4, you know, where we were in recurring revenue at the low end of our range, targeting acceleration in recurring revenue in 2022, and we are progressively doing that through Q1 and the rest of the year.
That's clear. Thank you.
Thank you.
Next question, please.
The next question from James Goodman from Barclays. Please go ahead.
Good morning. Thank you very much. Maybe we could pick up on 3DEXPERIENCE to begin with. Could you quantify, and apologies if I missed it, but the performance there on the license side this quarter, maybe just provide some broader context around the 3DEXPERIENCE adoption. It looked like it sort of slowed a little bit in terms of year-on-year growth in the fourth quarter, despite the overall license performance. Just wondering what the puts and takes there are. Then more broadly, could you perhaps make some commentary around the behaviors you're seeing from your customers in different industries as it relates to the supply chain constraints that are sort of so broadly impacting parts of your customer base at the moment?
I'm thinking about the opportunities it provides for Dassault, the necessity to sort of accelerate certain adoption of your solutions. Also whether there's been any timing impact from a financial perspective, just as a consequence of some of the challenges those businesses are facing. Thank you.
Rouven, you want to take the first one?
Yeah.
Before to do this, I want to make one comment.
Please.
Be careful not to look at only the license for 3DEXPERIENCE platform, because we are more and more subscriptions coming from 3DEXPERIENCE platform. If you are looking for an early indicators, of the momentum, you need to combine the two. Rouven, you could answer to the question.
I think we mentioned it before that for 3DEXPERIENCE, we saw very strong momentum in the fourth quarter in the subscription line. Overall very strong growth in 2022, with very healthy growth rates in total. When we look at Q4, you mentioned maybe some slowdown, if I correctly understood your question. I think Q4 was, you know, we were ahead of our consensus, our own objectives that we set. Q4 also, you have to factor in the year-over-year comparison. I think Q4 of 2020 was the first real benchmark for us in 2021. I think compared to that, we've shown very good durable growth.
I also want to highlight the fact that the growth was broad-based, right? If you look across the geos, if you look into Asia, for example, 12% growth. China, very, very strong growth. But also the resilience in Europe and core markets. Transportation, mobility, industrial equipment. It's really coming from the core industries and the core pillars of the company. Q4 was good.
On the supply chain side, it's a very interesting and challenging situation for many industries. I see three factors. I meet a lot of customers, thanks to Pascal, he's really running the operation, so I have time to spend with clients, and I love to do that. I see three factors, and many of them are not well understood by many observers in the economy. One of them is related to the effect of sustainability is reframing the value chain. Of course, the very first, which everyone talk about, is the availability of components on those kind of things. The second factor is related to the logistic. The third factor is related to the transformation of the supply chain to value chain. Let me comment on the three of them.
Of course, on the availability of certain resources, of components or materials, I think it's opening the eyes of many companies to better master the decision process of how they work with those suppliers.
Up to now, it was purely cost driven for years. In the last 15 years, I've been following this industry and transforming it for 40 years, I can tell you, and I have very precise data on it. Now it's moving from a cost to a more reliability, trust, and proximity. The second thing related to the supply chain is the reshaping of who plays in the value chain. Because when you create new product portfolio which are more sustainable, you change formulation for cosmetic, you change materials for manufacturing. This is going to accelerate. This is why we have a platform which is absolutely unique because we do those kind of simulation, the what if. Believe me, this is not the next two years.
This is for the next 20 years that it will drive the growth of what we do. Finally, on the logistics thing, yes, there was the congestion related to a slowdown and now a comeback, but I think there is a deeper problem, which is when people are going to start to seriously report ESG on the cost of logistics, they will change their mind about proximity. We talked about nearshoring in the past for engineering. It has happened in Europe, for example. We will see a new proximity in terms of production because the ESG factor on the sustainable reporting for companies is going to enforce to not optimize on cost, but optimize on other criteria. That's in short, where we are playing and why the platform is unique to solve it.
Very interesting. Thank you.
Next question, please.
Next question from Charles Brennan from Jefferies. Please go ahead.
Charles? Okay, Roberto, next question, please.
The next question from Amit Harchandani from Citi. Please go ahead.
Thank you. Good morning, all. Amit Harchandani from Citi. Two questions, if I may. My first question goes back to the performance in licenses and other. If you could please help us better understand the underlying drivers of the guidance for 2022 in terms of any particular product lines that you would call out, sectors or the underlying strength of 3DEXPERIENCE adoption. That would be the first question. The second question goes back to the topic of 3DEXPERIENCE more broadly. You've talked about it being 30% of software in 2021. The objective is two-thirds by 2025. Could you help us understand how we should think about the trajectory over the medium- term and as it may break down between licenses and recurring revenue? Thank you.
Thank you. Rouven, you take the first one, and we take the second one.
Sure, thank you for the question. We are, as discussed, for the license, we are projecting 10-12% license revenue growth year-over-year. It compares to 15% in Q4 of last year. What are the drivers? We have seen very durable performance of our major brands, of our major solutions of the platform. Certainly, if you look into our core markets of Industrial Innovation, which is back to 2019 levels.. We have a lot of our installed base that is constantly, you know, with very strong renewal rates, where we constantly expand our footprint in our core offerings.
I think that's where the majority of the license revenue in industrial innovation continues to come from. I mentioned that in my prepared remarks. It's because of our very strong installed base. Our license model is very well established. We see that to continue while we are increasing our recurring revenue by 100- 150 basis points in 2022. If you look into the life sciences sector, maybe to give you some color there, with the life sciences engagement that we've created two years ago, we talked about this, Pascal mentioned it. We are in a transition to accelerate the subscription revenue growth across, you know, the brands outside of Medidata, which is already fully subscription.
If you look into our mainstream market, of course, SOLIDWORKS has a strong installed base of licenses. As well, you know, with our focus on 3DEXPERIENCE and the SOLIDWORKS family, we are progressively moving towards a subscription and cloud model. Nevertheless, I think the 10%-12% license growth is on a very strong foundation for 2022.
Okay. Related to the 3DEXPERIENCE platform momentum and the KPI, which I shared with you at the capital market day almost three years ago. You have to remind something. When I did it was only on one sector of the economy, which was largely the manufacturing sectors. Now we are expanding into two new sector economy, which is life sciences and infrastructure, where the penetration rate of the 3DEXPERIENCE platform is low. And it's combined, it represent more than 30% of the total revenue of Dassault Systèmes. If you want to compute my number, you should keep in mind that when I gave to you the 2/3, was really related to the manufacturing sector first. Point number one. Point number two, if you look at all the industry within the manufacturing sectors, it's relatively simple.
The core industry, namely auto, transportation and mobility, aerospace and defense, industrial equipment, the penetration rate is between 40%-50%. If you look at the others, it's much more close to 20%, which is for you a way to understand where the levers are coming from. That's basically if you want to modelize and to follow this KPI in a proper way, the way you should look at it and how you should input your model in order to assess if we walk the talk.
Thank you, Pascal.
You're welcome.
Next, last question, please.
We have the next question from Frederic Boulan from Bank of America. Please go ahead.
Hi, good morning. Two questions from my side. First of all, on the life science segment, if you can spend a moment talking about your positioning in the value chain and is there any specific segment that you think could be interesting to develop further? On the infrastructure and cities segment, if you can discuss a little bit the traction you're having here, and if you think there is some need to develop either the product breadth or the distribution capabilities, either organically or non-organically. Thanks a lot.
Thank you, Frederic. On the positioning on the value chain for life science, I think we are demonstrating that the Medidata enterprise solution can be massively expanded to become a platform for distributed clinical trial. I think that's a big step because it points out on the fact that one day we want to really have an infrastructure for patient journey. It's a good preparation for that. The second in the value chain, if I take your question exactly with the value chain, there is no doubt that this industry is far sub-optimized when it comes to production. It's far from what has been done in, I think it rich companies not optimizing at all their infrastructure for production, for bioreactors on new production infrastructure.
There is a lot to play there. If they are far from using the lean TPS of Toyota Production System, it's unknown to them. The reuse of equipment is very low. The agility to ramp up is far from being what it should be. I don't want to be negative on insulting our potential customers, but we understand what production is about. The certification process is document-based. This would never happen anymore for an airplane. That's on the value chain from producing things. If you think about personalized medicine, there is another phenomenon. We will have to have smaller units producing smaller quantity of very specific therapeutics. I think this is what Moderna has in mind. The industry is not ready for that.
On the front end, if I go now backward on the research, there is a lot to be done on, the, not only the clinical trial, we focus on that, but on the research lab, on the unification of, lab discipline, which is related to cooperation. Most of the companies in the pharma sector has massively fragmented R&D. Most of them. It's isolated R&D pieces that don't talk to each other. We see that now with 3DEXPERIENCE, OneLab. We are connecting the dots that never were connected before. Not to speak about the lab work itself, which by the way, if you go and visit, you would see that most of them are reentering data for lab. A lot of things to be done in value chain.
Of course, the companies are challenged. All of them are challenged on new therapeutics, new research. Maybe this is why this discipline of connecting on creating digital pipeline is not there. I think we are revealing to them now, we, Dassault Systèmes, with the new reach that we can do a lot more. I think it's not a negative comment to say that they are a solid decade behind other sectors and that we can make the difference going forward on the back. This is on the value chain.
Infrastructure, you want to say a few words?
Infrastructure, briefly, we continue to make showcases. As Pascal said, the way we are expanding just on width with all new projects, with new players involved on the same platform is just impressive. We need more of them. That's our challenge. On to your remark about, is it a question of portfolio or is it a question of reach on capacity? I would admit that we need to find ways to expand on the capacity because what we have offered up to now is working, giving results on conducting the transformation and capacity to reach is probably a weak point for Dassault Systèmes, to date.
Thank you. Very clear, Pascal. Thank you for the team.
Very good. Thank you very much, Pascal, Rouven. Thank you very much. I feel very comfortable with your great leadership. It's great news for me. I could spend more time with customers, and this is what I love on technology and science, too. With all of that, hopefully see you soon and enjoy your day. We will continue to walk the talk and be one of the best reliable company to deliver on what we said.
That concludes the conference for today.
Thank you, guys.
Thank you for participating. You may all disconnect.